Rogerio Bonassi Machado

Rogerio Bonassi Machado

Auto-generated profile, based on publicly available information

Rogerio Bonassi Machado

Obstetrics and Gynecology Department, Faculdade de Medicina de Jundiaí

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Menopause
Verified
Journal Article
Open access
LTLora Mph Todorova
Lora Mph Todorova
RBRogerio Bonassi
Rogerio Bonassi
FCFrancisco Javier Guerrero Carreño
Francisco Javier Guerrero Carreño
AHAngelica Lindén Hirschberg
Angelica Lindén Hirschberg
NYNese Yuksel
Nese Yuksel
JKJanet S. Kim
Janet S. Kim
Objective: This study investigated the prevalence and impact of moderate to severe vasomotor symptoms (VMS), related treatment patterns, and experiences in women. Methods: The primary objective was to assess the prevalence of moderate to severe menopause-related VMS among postmenopausal women aged 40 to 65 years in Brazil, Canada, Mexico, and four Nordic European countries (Denmark, Finland, Norway, and Sweden) using an online survey. Secondary objectives assessed impact of VMS among perimenopausal and postmenopausal women with moderate to severe VMS using the Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, Patient-Reported Outcomes Measurement Information System sleep disturbances assessment, and questions regarding treatment patterns and attitudes toward symptoms and available treatments. Results: Among 12,268 postmenopausal women, the prevalence of moderate to severe VMS was about 15.6% and was highest in Brazil (36.2%) and lowest in Nordic Europe (11.6%). Secondary analyses, conducted among 2,176 perimenopausal and postmenopausal women, showed that VMS affected quality of life across all domains measured and impaired work activities by as much as 30%. Greater symptom severity negatively affected sleep. Many women sought medical advice, but most (1,238 [56.9%]) were not receiving treatment for their VMS. The majority (>70%) considered menopause to be a natural part of aging. Those treated with prescription hormone therapy and nonhormone medications reported some safety/efficacy concerns. Conclusions: Among women from seven countries, moderate to severe menopause-related VMS were widespread, varied by region, and largely impaired quality of life, productivity, and/or sleep.

8 July 2022 in Climacteric
Verified
Journal Article
Closed access
LPL. M. Pompei
L. M. Pompei
RBR. Bonassi-Machado
R. Bonassi-Machado
MSM. L. Steiner
M. L. Steiner
IPI. M. Pompei
I. M. Pompei
NMN. R. de Melo
N. R. de Melo
CFC. E. Fernandes
C. E. Fernandes
This study aims to understand the epidemiological characteristics of Brazilian menopausal women, and their view on menopause hormone therapy (MHT).A national cross-sectional study with 1500 women b... 目的:了解巴西绝经期女性的流行病学特点及其对绝经期激素治疗(MHT)的看法。方法:采用横断面调查的方法, 对1500名年龄在45 ∼ 65岁的女性进行调查。结果:参与者的总体中位数年龄为52[47-56]岁, 其中绝经后亚组为55[52-59]岁。出现月经不调的中位数年龄为46[44-49]岁。绝经的中位数年龄为48[45-51]岁, 且各社会经济阶层无差异。更年期症状的总发生率为87.9%...

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
GOGlaucia Oliveira
Glaucia Oliveira
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
CACarolina María Artucio Arcelus
Carolina María Artucio Arcelus
LELarissa Neto Espíndola
Larissa Neto Espíndola
MRMaria Alayde Mendonça Rivera
Maria Alayde Mendonça Rivera
MWMaria Celeste Osorio Wender
Maria Celeste Osorio Wender
1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para [...] 1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para

1 June 2017 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
RMRogerio Bonassi Machado
Rogerio Bonassi Machado
IMIlza Maria Urbano Monteiro
Ilza Maria Urbano Monteiro
JMJarbas Magalhães
Jarbas Magalhães
CGCristina Aparecida Falbo Guazzelli
Cristina Aparecida Falbo Guazzelli
MBMilena Bastos Brito
Milena Bastos Brito
SFSilvio Antonio Franceschini
Silvio Antonio Franceschini
Unwanted pregnancy is a major public health problem both in developed and developing countries. Although the reduction in the rates of these pregnancies requires multifactorial approaches, increasing access to long-acting contraceptive methods can contribute significantly to change this scenario. In Brazil, gynecologists and obstetricians play a key role in contraceptive counseling, being decisive in the choice of long-acting reversible methods, characterized by intrauterine devices (IUDs) and the contraceptive implant. The vast scope due to the reduced number of situations to indicate long-acting methods should be emphasized in routine contraceptive counseling. On the other hand, gynecologists and obstetricians should adapt the techniques of insertion of long-acting methods, and engage in facilitating conditions to access these contraceptives through public and private health systems in Brazil. This study is part of a project called Diretrizes e Recomendações FEBRASGO (Guidelines and Recommendations of the FEBRASGO – Brazilian Federation of Gynecology and Obstetrics Associations from the Portuguese acronym). It aims to review the main characteristics of long-acting contraceptives and critically consider the current situation and future prospects to improve access to these methods, proposing practical recommendations of interest in the routine of gynecologists and obstetricians. A gravidez não planejada representa importante problema de saúde pública tanto em países desenvolvidos quanto naqueles em desenvolvimento. Embora a redução das taxas dessas gestações requeira abordagens multifatoriais, o aumento no acesso aos métodos contraceptivos de longa ação pode contribuir de forma expressiva na mudança desse cenário. No Brasil, os ginecologistas e obstetras têm papel fundamental no aconselhamento contraceptivo, sendo decisivos na escolha dos métodos reversíveis de longa ação, caracterizados pelos dispositivos intrauterinos (DIUs) e pelo implante anticoncepcional. A grande abrangência decorrente do pequeno número de situações que contraindicam os métodos de longa ação deve ser enfatizada no aconselhamento contraceptivo de rotina. Por outro lado, os ginecologistas e obstetras devem se adaptar às técnicas de inserção dos métodos de longa ação, bem como se engajar na facilitação de condições para o acesso a esses contraceptivos por meio do sistema de saúde pública e privada no Brasil. Este estudo, parte do projeto denominado “Diretrizes e Recomendações FEBRASGO”, tem por objetivo revisar as principais características dos contraceptivos de longa ação, além de considerar de forma crítica o panorama atual e as perspectivas futuras, visando melhorar o acesso a esses métodos, com recomendações práticas de interesse na rotina do ginecologista e obstetra. This study is part of the Guidelines and Recommendations of the FEBRASGO, and its authors are members of the Brazilian National Specialized Commission in Contraception. * This revision is part of the Project Series, Guidelines and Recommendations of the Federação das Associações de Ginecologia e Obstetrícia - FEBRASGO, elaborated by the Specialized National Committees in Contraception.

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
GOGlaucia Oliveira
Glaucia Oliveira
MAMaria Cristina Costa de Almeida
Maria Cristina Costa de Almeida
CACarolina María Artucio Arcelus
Carolina María Artucio Arcelus
LELarissa Neto Espíndola
Larissa Neto Espíndola
MRMaria Alayde Mendonça Rivera
Maria Alayde Mendonça Rivera
MWMaria Celeste Osorio Wender
Maria Celeste Osorio Wender
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,– [...] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,–

1 June 2019 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PGPaulo César Giraldo
Paulo César Giraldo
TSThais Coelho de Souza
Thais Coelho de Souza
GHGuilherme Lindman Henrique
Guilherme Lindman Henrique
IMIlza Monteiro
Ilza Monteiro
RARose Amaral
Rose Amaral
JSJosé Marcos Sanches
José Marcos Sanches
SUMMARY OBJECTIVE: To evaluate endocervical and vaginal environment changes in women using a levonorgestrel-releasing intrauterine system (LNG-IUS). METHODS: A quasi-experimental study included sixty women who had an LNG-IUS inserted in the Family Planning Clinic of UNICAMP between April and November of 2016. Women in reproductive age, non-pregnant, without the use of antibiotics and contraceptives seeking for LNG-IUS insertion were selected for this study. All women were evaluated with regard to vaginal and endocervical pH, vaginal and endocervical Gram-stained bacterioscopy, and Pap-smear before and two months after LNG-IUS insertion. Clinical aspects such as cervical mucus, vaginal discharge, and cervical ectopy were also observed. RESULTS: After LNG-IUS insertion, there was an increase in the following parameters: endocervical pH>4.5 (p=0.02), endocervical neutrophil amount (p<0.0001), vaginal cytolysis (p=0.04). There was a decrease in vaginal discharge (p=0.01). No statistically significant changes were found in vaginal pH, neutrophils amount in the vaginal mucosa, vaginal discharge appearance, vaginal candidiasis, bacterial vaginosis, vaginal coccobacillary microbiota, cervical mucus appearance, or cervical ectopy size. CONCLUSIONS: Short-term LNG-IUS use did not increase vulvovaginal candidiasis or bacterial vaginosis, and led to diminished vaginal discharge. Notwithstanding, this device promoted reactional changes in the vaginal and endocervical environment, without modification on cervical ectopy size.